Wordt geladen...
An antibody-interleukin 2 fusion protein overcomes tumor heterogeneity by induction of a cellular immune response.
Antibody-based therapies for cancer rely on the expression of defined antigens on neoplastic cells. However, most tumors display heterogeneity in the expression of such antigens. We demonstrate here that antibody-targeted interleukin 2 delivery overcomes this problem by induction of a host immune re...
Bewaard in:
| Hoofdauteurs: | , , , , |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
1996
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC38833/ https://ncbi.nlm.nih.gov/pubmed/8755561 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|